Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;11(11):986-98.
doi: 10.1016/S1474-4422(12)70190-4.

The link between the GBA gene and parkinsonism

Ellen Sidransky  1 , Grisel Lopez
Affiliations
Review

The link between the GBA gene and parkinsonism

Ellen Sidransky et al. Lancet Neurol. 2012 Nov.

Abstract

Mutations in the glucocerebrosidase (GBA) gene, which encodes the lysosomal enzyme that is deficient in Gaucher's disease, are important and common risk factors for Parkinson's disease and related disorders. This association was first recognised in the clinic, where parkinsonism was noted, albeit rarely, in patients with Gaucher's disease and more frequently in relatives who were obligate carriers. Subsequently, findings from large studies showed that patients with Parkinson's disease and associated Lewy body disorders had an increased frequency of GBA mutations when compared with control individuals. Patients with GBA-associated parkinsonism exhibit varying parkinsonian phenotypes but tend to have an earlier age of onset and more associated cognitive changes than patients with parkinsonism without GBA mutations. Hypotheses proposed to explain this association include a gain-of-function due to mutations in glucocerebrosidase that promotes α-synuclein aggregation; substrate accumulation due to enzymatic loss-of-function, which affects α-synuclein processing and clearance; and a bidirectional feedback loop. Identification of the pathological mechanisms underlying GBA-associated parkinsonism will improve our understanding of the genetics, pathophysiology, and treatment for both rare and common neurological diseases.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

We declare that we have no conflicts of interest.

Figures

Figure 1
Figure 1. The 16 centres that participated in the international collaborative study on the frequency of GBA mutations in Parkinson’s disease
The numbers shown are the number of patients from each centre. Numbers in parentheses are the number of GBA mutation carriers identified at each site. Numbers in red show centres that sequenced the GBA gene for genotyping.
Figure 2
Figure 2. Immunofluorescence assessment of glucocerebrosidase in Lewy bodies in patients with parkinsonism without and with GBA mutations
(A, B, and C) The substantia nigra area from a patient without GBA mutations stained for glucocerebrosidase (A, red) and α-synuclein (B, green). The merged image with the nuclear stain (blue) shows a paucity of glucocerebrosidase staining in the Lewy body structure (C). (D, E, and F) The substantia nigra area from a GBA mutation carrier stained for glucocerebrosidase (D, red) and α-synuclein (E, green) showing colocalisation and accumulation in the Lewy body structure (F).
Figure 3
Figure 3. The bidirectional loop theory
Decreased glucocerebrosidase increases the lysosomal concentrations of glucosylceramide, which increases the formation of soluble α-synuclein oligomers. These oligomers also disrupt transport of newly synthesised glucocerebrosidase between the endoplasmic reticulum and Golgi apparatus, further compounding the problem.
Figure 4
Figure 4. How mutant glucocerebrosidase might result in enhanced α-synuclein aggregation
(A) In the normally functioning lysosome, wild-type glucocerebrosidase might interact with α-synuclein, facilitating the lysosomal component of α-synuclein degradation. (B) In most cases, when glucocerebrosidase is mutated, α-synuclein remains in the monomeric form and other processes are active in its degradation. (C) In some patients, glucocerebrosidase is mutated and the cell is unable to degrade α-synuclein. Lysosomal function is compromised and increased oligomeric forms of α-synuclein lead to neuronal cell death and the development of parkinsonism. This situation might enhanced by ageing, when the number of lysosomes and lysosome function decrease and cellular α-synuclein concentrations increase.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gaucher P. De l’epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leucemie. PhD thesis: University of Paris; 1882.
    1. Beutler E, Grabowski G. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, et al., editors. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw-Hill; 2001. pp. 3635–3668.
    1. Zimran A. How I treat Gaucher disease. Blood. 2011;118:1463–1471. - PubMed
    1. Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics. 1989;4:87–96. - PubMed
    1. Winfield SL, Tayebi N, Martin BM, Ginns EI, Sidransky E. Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res. 1997;7:1020–1026. - PMC - PubMed

Publication types

Substances